<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT931-5396</title>
	</head>
	<body>
		<main>
			<p>930305 FT  05 MAR 93 / International Company News: Ares-Sorono rises 51% to Dollars 108m ARES-SERONO, the Geneva-based drugs and diagnostics group, reported net income up 51 per cent to Dollars 107.8m for the year to December 31 from Dollars 71.2m. The results, which included a Dollars 27m gain from the disposal of its over the counter division, was achieved on sales up 16.7 per cent to Dollars 854m from Dollars 732m. Excluding favourable currency, underlying sales growth was 15 per cent. Mr Fabio Bertarelli, chief executive, said the group had achieved strong growth in spite of the turmoil of the European monetary system and pressure on government reimbursement schemes. Turnover of the ethical drugs division increased 20.4 per cent to Dollars 752m from Dollars 625m. The group said each of its main therapeutic areas - infertility, immunology and paediatric endocrinology - increased sales by more than 20 per cent over the year. Sales of the diagnostics division fell 4.6 per cent to Dollars 101m from Dollars 106m. The company said that if the clinical chemistry sales were discontinued, then diagnostic sales increased 5 per cent. Group capital spending increased to Dollars 92.8m from Dollars 56.7m. Earnings per share for continuing operations increased to Dollars 21.38 from Dollars 18.66. The board recommended a dividend of SFr6.00 per bearer share and SFr2.40 per registered share.</p>
		</main>
</body></html>
            